Sterling Capital Management LLC boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 442.1% during the first quarter, HoldingsChannel.com reports. The fund owned 170,257 shares of the biopharmaceutical company’s stock after purchasing an additional 138,851 shares during the period. Sterling Capital Management LLC’s holdings in Bristol Myers Squibb were worth $10,326,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BMY. Cambient Family Office LLC raised its holdings in shares of Bristol Myers Squibb by 4.0% in the 1st quarter. Cambient Family Office LLC now owns 6,726 shares of the biopharmaceutical company’s stock worth $408,000 after buying an additional 260 shares in the last quarter. Lewis Asset Management LLC boosted its stake in Bristol Myers Squibb by 2.2% in the 1st quarter. Lewis Asset Management LLC now owns 11,551 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 253 shares in the last quarter. River Street Advisors LLC acquired a new stake in Bristol Myers Squibb in the 1st quarter valued at $300,000. Granite Islands Private Wealth LLC grew its position in Bristol Myers Squibb by 166.7% in the first quarter. Granite Islands Private Wealth LLC now owns 13,335 shares of the biopharmaceutical company’s stock valued at $809,000 after acquiring an additional 8,335 shares during the period. Finally, Venturi Wealth Management LLC raised its stake in Bristol Myers Squibb by 13.0% during the first quarter. Venturi Wealth Management LLC now owns 6,072 shares of the biopharmaceutical company’s stock worth $368,000 after acquiring an additional 697 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.
Insider Activity at Bristol Myers Squibb
In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.05% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on BMY
Bristol Myers Squibb Stock Performance
Shares of NYSE:BMY opened at $57.45 on Friday. The business has a fifty day moving average of $57.06 and a 200-day moving average of $57.27. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The firm has a market cap of $117.31 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
